EFB Dengue Literature Review

CD20

5 min read

CD20

Overview

CD20 (MS4A1) is a membrane-spanning calcium channel expressed on B lineage cells from the pre-B stage through mature B cells. Its expression is lost on plasma cells and plasmablasts, and is not present on early bone marrow B cell precursors. In B cell immunology, CD20 serves two roles: (1) as a flow cytometry marker that distinguishes mature B cells from plasma cells and plasmablasts, and (2) as the therapeutic target of rituximab (anti-CD20 monoclonal antibody), which depletes CD20⁺ B cells via ADCC, complement-dependent cytotoxicity, and apoptosis.

The absence of CD20 on plasmablasts and plasma cells has important implications: rituximab depletes the CD20⁺ B cell compartment but cannot directly eliminate ongoing antibody-secreting cells, leading to the dissociation between B cell depletion and serologic response observed in clinical trials.

Key Points from Literature

  • Plasmablast identification: Plasmablasts are CD20⁻, enabling their discrimination from CD20⁺ B cells. In flow cytometry, the combination CD38^high, CD19^low, CD20⁻ defines peripheral blood plasmablasts; CD38^high, CD19⁺, CD20⁺ defines the pre-GC (Bm2ʹ) population (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE, n=15 SLE patients, n=5 controls).

  • Indirect plasmablast depletion after rituximab: Despite being CD20⁻, circulating plasmablasts declined rapidly in select patients after rituximab (e.g., patient 11: 40% → 14% at 2 months). This implies a short-lived plasmablast pool continuously replenished by CD20⁺ B cell precursors. Plasmablasts that persist after CD20⁺ precursor depletion likely represent a long-lived subpopulation or cells homing to survival niches (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • CD20 downregulation upon B cell activation: B cell activation is associated with downregulation of surface CD20 via movement into lipid rafts and endocytosis — a potential mechanism for rituximab resistance in highly activated SLE B cells (Anolik et al. 2003, Eur J Immunol — cited but not yet ingested).

  • Residual B cells after effective depletion: After 95–99% B cell depletion, residual cells are predominantly switched memory with a CD20⁺ phenotype (CD20⁺, CD38^low, CD27⁺, IgD⁻). Their persistence may reflect trafficking from peripheral lymphoid tissue rather than incomplete depletion per se (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • CD20 depletion (rituximab) reduces ABC and DN frequencies in SLE. Anti-CD20 (rituximab), alongside anti-BAFF (belimumab), reduces both ABC and DN frequencies in the blood of SLE patients — evidence implicating these populations in autoimmune pathogenesis (consistent with the rituximab-driven resolution of DN expansion in Anolik2004 - Rituximab and B Cell Abnormalities in SLE). Counterpoint: murine ABCs resist anti-CD20/anti-BLyS depletion (Knox 2025), a species discordance flagged on the Age-Associated B Cell page (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Sachinidis 2020/2024 / Ramsköld 2019).

  • CD20 is deliberately not in the recommended seven-marker core — it earns its place only for ASC resolution. CD20 is described as “largely overlapping with CD19”, so the review keeps CD19 in the core and adds CD20 as an additional marker that “offers additional discriminating power to identify ASC”: human ASC downregulate CD20, and the CD27ʰⁱCD38ʰⁱ fraction contains both CD20⁻ ASC and a small CD20⁺ ASC fraction that a CD20-free panel cannot separate (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data). See Plasmablast.

  • CD20 downregulation as the readout of plasmablast commitment in a de novo differentiation system. After 6 days of coculture of resting allogeneic CD19⁺ B cells with DENV-2-infected monocytes (plus IL-2 and CpG), the dividing cells “expressed CD19 and downregulated CD20, characteristic of differentiating plasmablasts”, with CD20^lo appearing alongside a CD27⁺⁺CD38⁺⁺ gate that reached 22.8% of total B cells (versus 3.83% with B cells alone) (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, in vitro, 4 independent experiments with 4 healthy blood donors). Every other CD20⁻ plasmablast entry on this page is an ex vivo gating criterion; this is the same rule observed forming in culture from a resting starting population, which is the stronger form of the claim.

Contradictions & Debates

  • Pre-GC (Bm2ʹ) cells express CD20 and are therefore in principle susceptible to rituximab, yet patients with high pre-GC baseline frequencies were more likely to have incomplete depletion. Whether this reflects CD20 downregulation, intrinsic resistance, or ongoing antigen-driven GC reactions replenishing these cells faster than rituximab can deplete them is unresolved (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • CD20⁻/low as original dengue plasmablast gate criterion: In the first systematic dengue plasmablast study, Wrammert2012 defined plasmablasts as CD19⁺CD3⁻CD20⁻/low CD27^high CD38^high. The CD20⁻/low criterion is the core plasmablast discriminator, consistent with the SLE data. This gating was performed on whole blood with BD Trucount for absolute enumeration (see Wrammert2012 - Plasmablast Responses in Acute Dengue, 5-color conventional FCM).

  • CD20⁻ criterion in dengue plasmablast gate: In the GarciaBates2013 gating scheme, CD20⁻ combined with CD38⁺ within the CD27⁺CD21⁻ fraction distinguishes plasmablasts from activated memory B cells (CD20⁺CD38⁻/lo). This confirms the CD20⁻ plasmablast phenotype in dengue, consistent with SLE data (see GarciaBates2013 - Plasmablast Response and Dengue Severity, LSRII FCM).

  • CD20⁻/⁺ as primary PB vs. MBC discriminator in dengue clonal analysis: Appanna2016 used CD20 as the key bifurcation marker: CD19⁺CD20⁻CD27^hiCD38^hi for plasmablasts (days 3–7) vs. CD19⁺CD20⁺CD27⁺ for memory B cells (days 16–166). The clonal disconnect between these two CD20-defined compartments (very few shared CDR3s, all IgM) demonstrates that CD20 loss marks a functionally and clonally distinct effector population during acute dengue (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, FACSAria, n=12 dengue).

Plasmablast, Double-Negative B Cell, Age-Associated B Cell, CD19, CD38, Bm Classification, Germinal Center

Sources

Graph View

Backlinks